RABYD-VAX SIGNED
Development of a Next-Generation, Dual-Target Rabies/Flavivirus Infectious DNA (iDNA) Vaccine
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0RABYD-VAX project word cloud
Explore the words cloud of the RABYD-VAX project. It provides you a very rough idea of what is the project "RABYD-VAX" about.
Project "RABYD-VAX" data sheet
The following table provides information about the project.
| Coordinator |
KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address contact info |
| Coordinator Country | Belgium [BE] |
| Project website | https://rabyd-vax.eu/ |
| Total cost | 4˙113˙385 € |
| EC max contribution | 4˙113˙385 € (100%) |
| Programme |
1. H2020-EU.3.1.2. (Preventing disease) |
| Code Call | H2020-SC1-2016-RTD |
| Funding Scheme | RIA |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-01-01 to 2020-12-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | KATHOLIEKE UNIVERSITEIT LEUVEN | BE (LEUVEN) | coordinator | 1˙818˙113.00 |
| 2 | THE SECRETARY OF STATE FOR ENVIRONMENT, FOOD AND RURAL AFFAIRS | UK (LONDON) | participant | 827˙107.00 |
| 3 | STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER | NL (RIJSWIJK ZH) | participant | 818˙458.00 |
| 4 | SCIENSANO | BE (ELSENE) | participant | 649˙705.00 |
| 5 | INSTITUT SCIENTIFIQUE DE SANTE PUBLIQUE | BE (BRUXELLES) | participant | 0.00 |
Map
Project objective
Rabies is the deadliest disease on earth (99.9% fatality rate). Annually, ~58.000 people die from rabies, more than half of them are children. Many remain unvaccinated because of the high costs and the need for a cold-chain. Likewise, despite the existence of an excellent yellow fever (YF) vaccine, yearly ~30.000 people die of YF. The 80-year old low-tech production process does not allow to produce sufficient doses. There is now a real danger that major YF-outbreaks become uncontrollable. We aim at developing an efficient, safe, cheap, thermostable and easy-to-produce vaccine that can be needle-free administered, that protects against both rabies and YF, and that can be implemented in routine prophylactic paediatric vaccination. For this, we will employ our (P01a) proprietary infectious DNA (iDNA) vaccine technology. Simple, even needle-free injection of a low dose (1-10µg) of this easy-to-produce naked plasmid in mice and hamsters launches the YF vaccine virus and protects hamsters as efficiently as the commercial vaccine against lethal YF challenge. The iDNA YF vaccine will be used as vector to express relevant protective rabies antigens. Dual protection of such chimeric iDNA rabies/YF vaccine will be demonstrated against lethal rabies and YFV challenge in small animal models. Likewise, chimeric rabies/Japanese encephalitis and rabies/Zika virus iDNA vaccine candidates will be generated using this versatile platform. Next, induction of protective immunity will be demonstrated in rhesus macaques. The iDNA vaccines combine the benefits of both the YF live-attenuated vaccine (highly efficient life-long induction of immunity) and the thermo-stability, ease-of-production and the potential to customize (in response to emerging medical needs) of “classical” DNA vaccines. A path towards advanced pre-clinical and clinical development of such novel vaccines will be developed in compliance with European regulatory and WHO prequalification requirements.
Deliverables
| Dissemination and Communication Measures | Documents, reports | 2019-05-31 16:34:02 |
Take a look to the deliverables list in detail: detailed list of RABYD-VAX deliverables.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2019 |
Rebecca Shipley, Edward Wright, David Selden, Guanghui Wu, James Aegerter, Anthony R Fooks, Ashley C Banyard Bats and Viruses: Emergence of Novel Lyssaviruses and Association of Bats with Viral Zoonoses in the EU published pages: 31, ISSN: 2414-6366, DOI: 10.3390/tropicalmed4010031 |
Tropical Medicine and Infectious Disease 4/1 | 2020-03-11 |
| 2018 |
Dieudonné B. Kum, Niraj Mishra, Robbert Boudewijns, Ivan Gladwyn-Ng, Christian Alfano, Ji Ma, Michael A. Schmid, Rafael E. Marques, Dominique Schols, Suzanne Kaptein, Laurent Nguyen, Johan Neyts, Kai Dallmeier A yellow fever–Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice published pages: , ISSN: 2059-0105, DOI: 10.1038/s41541-018-0092-2 |
npj Vaccines 3/1 | 2020-03-11 |
| 2018 |
Ashley C. Banyard, David Selden, Guanghui Wu, Leigh Thorne, Daisy Jennings, Denise Marston, Stefan Finke, Conrad M. Freuling, Thomas Müller, Juan E. EchevarrÃa, Anthony R. Fooks Isolation, antigenicity and immunogenicity of Lleida bat lyssavirus published pages: 1590-1599, ISSN: 0022-1317, DOI: 10.1099/jgv.0.001068 |
Journal of General Virology 99/12 | 2020-03-11 |
| 2019 |
Dieudonné Buh Kum, Niraj Mishra, Bram Vrancken, Hendrik Jan Thibaut, Annelies Wilder-Smith, Philippe Lemey, Johan Neyts, Kai Dallmeier Limited evolution of the yellow fever virus 17d in a mouse infection model published pages: 1734-1746, ISSN: 2222-1751, DOI: 10.1080/22221751.2019.1694394 |
Emerging Microbes & Infections 8/1 | 2020-03-11 |
| 2019 |
Samuel P. Smith, Guanghui Wu, Anthony R. Fooks, Julian Ma, Ashley C. Banyard Trying to treat the untreatable: experimental approaches to clear rabies virus infection from the CNS published pages: 1171-1186, ISSN: 0022-1317, DOI: 10.1099/jgv.0.001269 |
Journal of General Virology 100/8 | 2020-03-11 |
| 2018 |
Jennifer Evans, Guanghui Wu, David Selden, Hubert Buczkowski, Leigh Thorne, Anthony Fooks, Ashley Banyard Utilisation of Chimeric Lyssaviruses to Assess Vaccine Protection against Highly Divergent Lyssaviruses published pages: 130, ISSN: 1999-4915, DOI: 10.3390/v10030130 |
Viruses 10/3 | 2019-06-11 |
| 2018 |
E. Kip, J. Staal, L. Verstrepen, H. G. Tima, S. Terryn, M. Romano, K. Lemeire, V. Suin, A. Hamouda, M. Kalai, R. Beyaert, S. Van Gucht MALT1 Controls Attenuated Rabies Virus by Inducing Early Inflammation and T Cell Activation in the Brain published pages: , ISSN: 0022-538X, DOI: 10.1128/JVI.02029-17 |
Journal of Virology 92/8 | 2019-06-11 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RABYD-VAX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "RABYD-VAX" are provided by the European Opendata Portal: CORDIS opendata.